Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b). Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
and N-acetylcysteine when combined together decreases FVC decline and some studies even represent the prolonged PFS in the intervention group. However, the studies revealed adverse events to have caused in the intervention group more which is associated with the fact that patients in the intervention group received high dose of combined drug and prolonged use of the same. Furthermore, these researches further revealed that the combined treatment method is suggested for patients with mild, moderate and intense levels of IPF; however the interpretation lacks generalisation due to low sample size. In addition, the assessment of likelihood of combination therapy towards decreasing IPF based mortality rate revealed reduction of adverse effects of IPF in all studies which warrant that the combined treatment, to some extent aid reduction of rate of mortality in patients with IPF. For the management of IPF, careful examination of the individual patient characteristics and factors such as anatomic and physiologic variables is required so as to decide whether individual or combined treatment modality could be used in the case of IPF. 5.5 Recommendations All the previous researches considered for the systematic review and meta-analyses possess limitations which affect concluding the benefits of the combined drug treatment. As a common limitation, all studies lack generalisation of results as the sample size is relatively low. Furthermore, this might affect the use of pirfenidone and N-acetylcysteine as a combined drug treatment for IPF. Secondly, the duration for research is less which further affects the findings of each study. Hence, the study recommends future researches to consider a sample size which can effectively validate the outcomes of all the previous researches. © 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent Tutors India - Your trusted mentor since 2001 www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com Page 108 of 172
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent Tutors India - Your trusted mentor since 2001 www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com Page 109 of 172
- Page 79: to NAC inhaled inhaled NAC and oral
- Page 82: S. no Author; Year 1 Behr et al 7 C
- Page 86: pirfenidone combined with highdose
- Page 90: or temporary cessation of pirfenido
- Page 93: 4.5 Patient characteristics, interv
- Page 97: oom air 3 Sakamoto et al 15 Effecti
- Page 101 and 102: Of the studies considered for the s
- Page 103: 4.6 Evaluation of Efficacy of Prife
- Page 107: change in the lowest SPO2 during th
- Page 111: PaO2, and SaO2; episodes of AE-IPF
- Page 115 and 116: The efficacy of using NAC in combin
- Page 117 and 118: group. It is revealed that at the 2
- Page 119 and 120: CHAPTER V: DISCUSSION AND CONCLUSIO
- Page 121 and 122: contradicting results 50 51 . A res
- Page 123 and 124: tolerability and safety of pirfenid
- Page 125 and 126: equired. An exploratory efficacy an
- Page 127: as to verify the results and acquir
- Page 131 and 132: American Thoracic Society. Idiopath
- Page 133 and 134: and clinical immunology. 115 (1). p
- Page 135 and 136: Behr, J., Maier, K., Degenkolb, B.,
- Page 137 and 138: Bowling, A. (2009). Research Method
- Page 139 and 140: 878-81. Available from: http://www.
- Page 141 and 142: http://www.ncbi.nlm.nih.gov/pubmed/
- Page 143 and 144: El-Chemaly, S., Ziegler, S.G., Cala
- Page 145 and 146: Flaherty, K.R., Andrei, A.-C., Murr
- Page 147 and 148: pirfenidone on the generation of re
- Page 149 and 150: Hansell, D.M., Bankier, A.A., MacMa
- Page 151 and 152: proteoglycan deposition in the airw
- Page 153 and 154: Nishimura, J. & Inoue, T. (2009). A
- Page 155 and 156: 313-9. Available from: http://www.n
- Page 157 and 158: Pereira, C.A., Sahn, S.A., Sussman,
- Page 159 and 160: interstitial pneumonia: the prognos
- Page 161 and 162: Leslie, K.O., Gruden, J.F., Parish,
- Page 163 and 164: America. 25 (4). pp. 709-721. Marti
- Page 165 and 166: Meyer, A., Buhl, R. & Magnussen, H.
- Page 167 and 168: Moseley, P.L., Hemken, C. & Hunning
- Page 169 and 170: topics/topics/idiopathic-pulmonary-
- Page 171 and 172: Olson, A.L., Swigris, J.J., Lezotte
- Page 173 and 174: Piguet, P.F., Vesin, C., Grau, G.E.
- Page 175 and 176: open-label Phase II study. American
- Page 177 and 178: Rødningen, O.K., Børresen-Dale, A
and N-acetylcysteine when combined together decreases FVC decline and some studies even<br />
represent the prolonged PFS in the intervention group. However, the studies revealed adverse<br />
events to have caused in the intervention group more which is associated with the fact that<br />
patients in the intervention group received high dose of combined drug and prolonged use of<br />
the same. Furthermore, these researches further revealed that the combined treatment method<br />
is suggested for patients with mild, moderate and intense levels of IPF; however the<br />
interpretation lacks generalisation due to low sample size. In addition, the assessment of<br />
likelihood of combination therapy towards decreasing IPF based mortality rate revealed<br />
reduction of adverse effects of IPF in all studies which warrant that the combined treatment,<br />
to some extent aid reduction of rate of mortality in patients with IPF. For the management of<br />
IPF, careful examination of the individual patient characteristics and factors such as anatomic<br />
and physiologic variables is required so as to decide whether individual or combined<br />
treatment modality could be used in the case of IPF.<br />
5.5 Recommendations<br />
All the previous researches considered for the systematic review and meta-analyses possess<br />
limitations which affect concluding the benefits of the combined drug treatment. As a<br />
common limitation, all studies lack generalisation of results as the sample size is relatively<br />
low. Furthermore, this might affect the use of pirfenidone and N-acetylcysteine as a<br />
combined drug treatment for IPF. Secondly, the duration for research is less which further<br />
affects the findings of each study. Hence, the study recommends future researches to consider<br />
a sample size which can effectively validate the outcomes of all the previous researches.<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 108 of 172
Change language